{
 "context": "The following article called 'Novartis Blurs Vision of Its Potential' was published on 2015-07-21. The body of the article is as follows:\n    \nNovartis Blurs Vision of Its Potential Problems in its eye-care business Alcon hurt second-quarter earnings By July 21, 2015 10:24 a.m. ET \nNovartis has taken one in the eye. \nFlat sales in its eye-care business, Alcon, which accounts for about a fifth of revenues, hit second-quarter results. That sent the stock skidding, despite strong results in its pharmaceuticals and generics units. The result also dashed hopes for an increase in its full-year guidance and emphasizes that the Swiss company\u2019s challenge is to live up to high expectations. \nNovartis in many ways... To Read the Full Story, Subscribe or Sign In Popular on WSJ\n\n    The day before the article was published, the stock price of Novartis AG was 76.55753326416016 and the day after the article was published, the stock price of Novartis AG was ",
 "expected": "73.08027648925781",
 "date": "2015-07-21",
 "ticker": "NVS",
 "company": "Novartis AG"
}